Enjoy complimentary customisation on priority with our Enterprise License!
The radioimmunoassay market size is forecast to increase by USD 1.73 billion at a CAGR of 4.82% between 2023 and 2028. The market is experiencing significant growth due to the expansion of the pharmaceutical and biotechnology industries. This growth is driven by the increasing demand for accurate and efficient diagnostic tools for various diseases and substances, including vitamins, medicines, and chronic infections. The aging population and the prevalence of chronic illnesses such as diabetes, cardiology, and endocrinology are key factors fueling this demand. RIA is widely used for disease diagnosis, kit development, and therapeutic drug monitoring in various sectors, including clinics and diagnostic centers. The market is witnessing a shift towards automation and integration into RIA systems, which is increasing the adoption of these technologies by businesses. However, competition from alternative technologies, such as ELISA and chemiluminescence assays, is posing a challenge to the market growth. The rise in the prevalence of infectious diseases and the need for quick and accurate diagnosis are also driving the market.
Radioimmunoassays (RIAs) are essential tools in the field of diagnostic healthcare and research. These immunoassays utilize radioactivity and radioisotope for the detection of specific antigens or hormones in medical samples. The technique involves the use of antibodies to bind with the target antigen, which is then measured by the emitted radioactivity. The RIA market has been growing steadily due to its high sensitivity and specificity, making it an essential method in various diagnostic applications. In healthcare, RIAs are widely used for the detection and quantification of various hormones, such as insulin, thyroid hormones, and cortisol.
Additionally, RIAs play a crucial role in research, particularly in the fields of endocrinology, immunology, and pharmacology. The use of radioisotopes in RIAs offers several advantages over other immunoassay techniques. The high sensitivity of RIAs enables the detection of low concentrations of antigens, making it an ideal method for the diagnosis of various medical conditions. Furthermore, RIAs offer a high degree of accuracy and precision, which is essential in the diagnostic industry. The growth of the RIA market can be attributed to the increasing demand for accurate and reliable diagnostic tests in healthcare. With the growing prevalence of chronic diseases, such as diabetes and thyroid disorders, the need for sensitive and specific diagnostic tests is on the rise.
Furthermore, the development of new applications for RIAs in research and pharmaceutical industries is expected to fuel the market growth. The RIA market faces competition from other immunoassay techniques, such as enzyme-linked immunosorbent assays (ELISAs) and chemiluminescent immunoassays (CLIAs). However, RIAs continue to hold a significant market share due to their high sensitivity and specificity, making them an essential tool in the diagnostic and research industries. In conclusion, the RIA market is expected to continue its growth trajectory due to the increasing demand for accurate and reliable diagnostic tests in healthcare and research. The technique's high sensitivity and specificity, coupled with the advantages offered by radioisotopes, make RIAs an essential tool in the diagnostic and research industries.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The clinical diagnostics segment is estimated to witness significant growth during the forecast period. In the realm of clinical diagnostics, radioimmunoassay (RIA) holds significant importance, fueling the expansion of The market. The technique is predominantly used in endocrine testing for the precise quantification of hormones, including insulin, thyroid hormones, cortisol, and growth hormones. This aids clinicians in diagnosing and managing disorders such as diabetes, thyroid dysfunction, and adrenal insufficiency. Furthermore, RIA finds extensive application in oncology for tumor marker testing, contributing to early cancer detection and treatment response monitoring. Tumor markers like prostate-specific antigen (PSA), alpha-fetoprotein (AFP), and carcinoembryonic antigen (CEA) can be accurately measured using RIA. Collaborations among market players and research institutions are a key trend in the market.
However, the high cost of reagents and specialized training required for RIA pose restraining factors. The use of stable free radicals, fluorochromes, and enzyme inhibitors in RIA methods enhances sensitivity and specificity. License agreements and containment measures ensure product quality and safety. Despite these challenges, the North American region is expected to dominate the market due to the presence of major market players and advanced healthcare infrastructure. The market for radioimmunoassay products is expected to continue its growth trajectory, driven by the increasing prevalence of diseases and the need for accurate diagnostic tools.
Get a glance at the market share of various segments Request Free Sample
The clinical diagnostics segment was valued at USD 3.06 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The North American region holds a substantial position in the market. Factors such as technological innovations, rising healthcare expenditure, and a high incidence of chronic diseases contribute to its growth. In the US and Canada, radioimmunoassays are extensively utilized in clinical diagnostics, pharmaceutical research, and academic institutions. The increasing prevalence of diseases like diabetes, cancer, and cardiovascular disorders necessitates the use of precise diagnostic tools, thereby fueling market expansion. Furthermore, supportive government initiatives focusing on early disease detection and personalized medicine add impetus to the market's growth. Key players in the region, coupled with advanced healthcare infrastructure and a strong research and development focus, create a competitive landscape in the market. Radioimmunoassays, a type of immunoassay, utilize radioisotopes for detection, offering high sensitivity and specificity. Other immunoassay techniques, such as ELISA, also find extensive application in various industries. The radioimmunoassays market in North America is expected to grow, driven by these factors.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The expansion of the pharmaceutical and biotechnology industries is the key driver of the market. The Radioimmunoassay (RIA) market experiences steady growth due to its extensive use in clinical laboratories and research institutions. This in-vitro assay technique plays a crucial role in measuring the binding affinity between antigens and antibodies, enabling the quantification of various proteins, hormones, drug levels, and biomarkers. The healthcare sector, particularly in the US, heavily relies on RIA for diagnostic procedures, including the detection of abused drugs, cancer markers, peptic ulcers, neurotransmitters, infections, and allergens. The pharmaceutical and biotechnology industries' expansion fuels the demand for RIA, as it is an essential tool for drug development, pharmacokinetic studies, and biomarker analysis.
Furthermore, the biotechnology sector's growth, driven by advancements in gene therapy, personalized medicine, and biologics, further increases the need for RIA. In oncology testing, RIA is used to measure immune checkpoint proteins like PD-L1, facilitating the development of immunotherapies for cancer treatment. In toxicology testing, RIA helps determine drug levels in various biological samples, ensuring patient safety. The automation and high-throughput capabilities of RIA make it an attractive choice for researchers and clinicians, enhancing efficiency and reducing errors. The increasing urbanization and hospitalization rates in the US also contribute to the market's growth, as more people require diagnostic tests and therapeutic interventions.
Shift towards automation and integration into radioimmunoassay systems is the upcoming trend in the market. The Radioimmunoassay (RIA) market in the US is witnessing significant growth due to the increasing demand for accurate and efficient diagnostic solutions for various chronic illnesses and diseases. This market is driven by the rising prevalence of chronic infections, diabetes, and other prevalent chronic illnesses, necessitating the development of advanced diagnostic kits. The adoption of RIA technology is on the rise in various industries, including clinics and diagnostic centers, due to its ability to measure the Somatostatin content and Delta-cell number, which are crucial markers for certain medical conditions. Moreover, the integration of automation and advanced technology in RIA systems is a notable trend in the market.
Furthermore, businesses are investing in fully automated RIA systems that offer walk-away capabilities and integrate with Laboratory Information Management Systems (LIMS) and other laboratory automation solutions. For instance, Siemens Healthineers AG's IMMULITE 2000 XPi Immunoassay System offers automation capabilities for radioimmunoassays, enhancing laboratory productivity and reducing turnaround times. RIA technology is also gaining traction in therapeutic drug monitoring, cardiology, endocrinology, and infectious diseases. Handheld gadgets and portable RIA systems are becoming increasingly popular due to their convenience and ease of use. The market is expected to continue growing due to the increasing need for precise and timely diagnosis and monitoring of various medical conditions.
The rise in competition from alternative technologies for radioimmunoassays is a key challenge affecting the market growth. The market faces significant competition from alternative diagnostic technologies, such as enzyme-linked immunosorbent assays (ELISA) and chemiluminescence immunoassays (CLIA). Although radioimmunoassays provide high sensitivity and specificity, these competing technologies offer comparable or superior performance characteristics with non-radioactive components, making them safer and more eco-friendly. ELISA assays, in particular, can be easily automated, resulting in increased throughput and decreased turnaround times. CLIA assays, on the other hand, utilize chemiluminescent signals for detection, providing enhanced sensitivity and a broader dynamic range than radioimmunoassays. Physician offices, patient self-testing centers, blood banks, home health agencies, nursing homes, and ambulatory surgical centers continue to use radioimmunoassay analyzers for the detection of various biomarkers, including those for HIV, cardiovascular diseases, and chronic diseases.
Furthermore, radioimmunoassay kits and equipment employ radioactive material for the formation of antigen-antibody complexes using labelled antigens or unlabelled antigens and antibody sites. These complexes are then measured using a bioassay to determine the concentration of the specific compound in a sample. Tumour indicators, peptides, steroids, and other compounds can be detected using radioimmunoassays. However, the increasing popularity of ELISA and CLIA assays may impact the growth of the market.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
ALPCO: The company offers radioimmunoassay such as Cortisol Radioimmunoassay RIA, which is for the Quantitative Determination of Free Cortisol in Human, serum, plasma, urine, and now saliva samples.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The in-vitro assay technique known as radioimmunoassay (RIA) plays a significant role in diagnostic procedures and research fields, particularly in the measurement of proteins, hormones, and other substances in blood and other biological samples. This technique is based on the principle of antibody-antigen binding and the detection of radioactivity. RIA is widely used in clinical laboratories for diagnosing various diseases and disorders, including cancer, peptic ulcers, neurotransmitters imbalances, infections, and allergens. It is also used in oncology and toxicology testing, as well as in therapeutic drug monitoring and drug addiction treatment. The RIA market is driven by the increasing prevalence of chronic diseases, such as diabetes, HIV, and cardiovascular diseases, which require regular monitoring and diagnosis.
Furthermore, the market is also influenced by the availability of high-throughput and automated procedures, collaborations between businesses and academics, and the development of new radioimmunoassay kits and equipment. The market landscape is diverse, with various product types, including radioimmunoassay analyzers, radioimmunoassay kits, and radioimmunoassay equipment, used in hospitals, clinics, diagnostic centers, blood banks, home health agencies, nursing homes, ambulatory surgical centers, and patient self-testing centers. The market is also impacted by factors such as the cost of expensive reagents, licensing, containment, and special training requirements. The RIA market is expected to grow significantly in North America, Europe, China, and other regions, with a focus on the development of sensitive and specific assays for various applications.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
150 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 4.82% |
|
Market Growth 2024-2028 |
USD 1.73 billion |
|
Market structure |
Concentrated |
|
YoY growth 2023-2024(%) |
3.83 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 40% |
|
Key countries |
US, Canada, UK, Germany, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
ALPCO, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biocompany Laboratorni medicina AS, Danaher Corp., Enzo Biochem Inc., Merck KGaA, MP BIOMEDICALS, OriGene Technologies Inc., PerkinElmer Inc, Siemens Healthineers AG, Tecan Trading AG, and Thermo Fisher Scientific Inc. |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
